Rated 4.9 out of 5 by our fellas WEIGHT LOSS TREATMENTS
Studies show that a loss of muscle mass has been associated with a reduced ability to maintain weight loss, as well as accelerated biological aging
This personalized approach ensures you start with the medication most likely to produce your best results

According to the financial reports by Novo Nordisk, the business revenue of GLP-1 RAs has reached 34,653 million Danish krone (DKK) in the first quarter of 2023 ( The FDA Adverse Event Reporting System (FAERS) is a robust pharmacovigilance database that contains real-world data on AE reporting ( Methods Data sources FAERS is an openly accessible pharmacovigilance database documenting AEs, medication errors, and product quality complaints reported spontaneously by people of diverse occupations worldwide ( Data extraction In order to acquire AE reports data treated with GLP-1 RAs, we identified the AEs of GLP-1 RAs in the DRUG files using the generic and brand names of the FDA-approved GLP-1 RAs, specifically exenatide (BYETTA, BYDUREON), liraglutide (VICTOZA, SAXENDA), lixisenatide (ADLYXIN, SOLIQUA), dulaglutide (TRULICITY), semaglutide (OZEMPIC, RYBELSUS, WEGOVY), and tirzepatide (MOUNJARO)

10.4103/NRR.NRR-D-23-01508 [DOI] [PMC free article] [PubMed] [Google Scholar] Zitka O., Skalickova S., Gumulec J., Masarik M., Adam V., Hubalek J., et al